Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma

Human CD4+ T Cells Recognize an Epitope within  -Fetoprotein Sequence and Develop into TGF- -Producing CD4+ T Cells

(2014) A. Alisa et al.   JOURNAL OF IMMUNOLOGY

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

(2013) Carmen Berasain   GUT

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

(2013) Martin Franz Sprinzl et al.   HEPATOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity

(2013) Mei-Ling Chen et al.   INTERNATIONAL JOURNAL OF CANCER

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

(2013) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

(2012) Roniel Cabrera et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model

(2011) Mengde Cao et al.   LABORATORY INVESTIGATION

A Novel Phycobiliprotein Alleviates Allergic Airway Inflammation by Modulating Immune Responses

(2010) Chun-Jung Chang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Lenalidomide mode of action: linking bench and clinical findings

(2010) Faith Davies et al.   BLOOD REVIEWS

PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

(2010) Feng Shi et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

(2010) Ying-Chun Shen et al.   JOURNAL OF GASTROENTEROLOGY

Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors

(2010) Barbara Seliger et al.   TRENDS IN MOLECULAR MEDICINE

Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma

(2009) D.-L. Ou et al.   CLINICAL CANCER RESEARCH

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B

(2009) Paola Fisicaro et al.   GASTROENTEROLOGY

The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro

(2009) M. Krusch et al.   JOURNAL OF IMMUNOLOGY

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib

(2009) R. Houben et al.   MOLECULAR CANCER THERAPEUTICS

Microanatomy of the liver immune system

(2009) Eszter Nemeth et al.   Seminars in Immunopathology

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide

(2008) Q. Zhou et al.   CLINICAL CANCER RESEARCH

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

(2008) W Zhao et al.   LEUKEMIA

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE